Beam Therapeutics Q2 2020 Earnings Report
Key Takeaways
Beam Therapeutics reported pipeline updates, recent business highlights and second quarter 2020 financial results, highlighted by the naming of BEAM-101 and BEAM-102 as development candidates for sickle cell disease.
Named BEAM-101 and BEAM-102 as development candidates targeting distinct approaches to treating sickle cell disease.
Signed lease agreement to build in-house manufacturing facility dedicated to producing base editing therapeutics.
Continued to advance and expand the therapeutic application of novel base editing technologies through a broad partnering strategy.
Team remains on track to initiate IND-enabling studies in 2020 and file at least one Investigational New Drug application in 2021.
Beam Therapeutics
Beam Therapeutics
Forward Guidance
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the expected timing of filing INDs applications, the therapeutic applications of our technology and our ability to develop base editors as a new class of precision genetic medicines for patients.